Drug Profile


Alternative Names: anti-CD26 begelomab; Begedina; BT 5/9; murine anti-CD26 BT 5/9; SAND-26

Latest Information Update: 22 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ADIENNE
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action CD26 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Graft-versus-host disease

Most Recent Events

  • 30 Jan 2018 ADIENNE initiates enrolment in a phase I/II trial for Graft-versus-Host Disease in Italy (EudraCT2017-002715-34)
  • 04 Jul 2016 ADIENNE withdraws MAA application filed with the EMA for begelomab (0.9 mg/ml) for Graft versus host disease in European Union (IV)
  • 01 Feb 2016 Phase-II/III clinical trials in Graft-versus-host disease in USA, and Switzerland (IV) (NCT02411084)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top